« Return to News | Ethics/Regulatory

FDA says drug approvals highest in two decades

Friday, July 8, 2011 02:15 PM

Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, testified before the U.S. House Energy and Commerce's health subcommittee that first-cycle drug approvals are at a 20-year high, and more than two-thirds of new treatments are being cleared within the time frames given to new drug applications.

The director also noted the agency approved 20 compounds so far this year, one less than the total for all of 2010, and that the FDA meets more than 90% of drug-review deadlines, according to FirstWord.  

At the hearing, Woodcock fielded questions regarding the FDA’s regulatory process, which some lawmakers suggested "has become less transparent and [has] increased the time it takes for products to reach those who need them." However, she proposed that challenges being faced by the biotechnology and pharmaceutical industries are related to high failure rates of drugs in development rather than the FDA's regulations.

OncoMed Pharmaceuticals CEO Paul Hastings, who also testified at the hearing, said "regulatory uncertainty, longer drug development timelines and an increasing regulatory and Congressional focus on risk instead of reward in pharmaceutical innovation deters limited partners from investing in biotech venture capital firms and subsequently deters venture capitalists from investing in biotechnology discovery companies."

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.